Responses
Original research
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.